BI-1206

BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B) . BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) [1][3].

Product Specifications

UNSPSC

12352203

Target

CD20; Fc Receptor (FcR)

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Smiles

[BI-1206]

References & Citations

[1]Jiang VC, et al., Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma. J Hematol Oncol. 2022 Apr 11;15 (1) :42. |[2]Changying Jiang, et al., BI-1206, a Monoclonal Antibody Against Fcγriib, Showed Superior Anti-Tumor Activity in an Ibrutinib-Venetoclax Dual Resistant PDX Model in Mantle Cell Lymphoma, Blood, Volume 134, Supplement 1, 2019, Page 2863, ISSN 0006-4971. |[3]Mårtensson, L.et al., A novel FcγRIIB-blocking antibody to enhance FcγR-dependent antitumor immunity with anti-HER2 therapy[J]. Cancer Research, 2022, 82 (12_Supplement) : 3423-3423.